Warren Woessner is a registered patent attorney and a founding shareholder of Schwegman, Lundberg & Woessner. His practice focuses on chemical patent law, including biotechnology, pharmaceuticals, vaccines, medical treatments, diagnostics, and biofuels and agricultural chemistry, including related opinion and licensing matters.
Warren received his B.A. in chemistry (1966) from Cornell University, his Ph.D. (organic chemistry, 1971) and his law degree (J.D., cum laude, 1981) from the University of Wisconsin – Madison. From 1972-1978 he worked for Miles Laboratories in new drug research. Warren was an associate attorney at Kenyon & Kenyon from 1981-1984, and then joined Merchant & Gould in Minneapolis. He founded their chemical practice group and became a partner in 1989. Warren also co-founded the Biotechnology Committee of the Minnesota Intellectual Property Law Association. He has published and spoken widely on legal topics, was the 1993-1995 chair of the Chemical Practice Committee of the American Intellectual Property Law Association, chaired the Biotechnology Committee (2003-2005) and has served as a member of the Amicus Committee. He co-authored the AIPLA amicus briefs to the Federal Circuit and the Supreme Court in J.E.M. Ag Supply v. Pioneer Hi-Bred. Warren is a Certified Licensing Professional
More Legal and Business Bylines From Warren Woessner
- Is the Patent Eligibility Act a Panacea for Claims to Diagnostics? - (Posted On Monday, January 29, 2024)
- Federal March-In Rights Meet Clawbacks – The Future of 35 USC ss. 200-212 - (Posted On Thursday, January 11, 2024)
- The Tyranny of Large Numbers: Their Grip on s. 102 Inquiries - (Posted On Saturday, October 07, 2023)
- Does the “Patent Eligibility Restoration Act of 2023” Revive Diagnostic Claims? - (Posted On Monday, June 26, 2023)
- Supreme Court Voids Amgen’s Patents using “Undue Experimentation” Standard - (Posted On Monday, May 22, 2023)
- Chromadex v. Elysium Health – It’s Only Natural! - (Posted On Friday, February 24, 2023)
- PTO Expands the Scope of the Immunotherapy Pilot Program - (Posted On Wednesday, December 21, 2022)
- Moderna to Pfizer: “The Pandemic is Over” - (Posted On Tuesday, September 06, 2022)
- Tillis Bill Tries to Fix Section 101 - (Posted On Monday, August 08, 2022)
- CareDx v. Natera – The Broad Road to Patent Ineligibility - (Posted On Thursday, July 21, 2022)
The National Law Review has awarded Warren Woesssner, shareholder at Schwegman, Lundberg & Woessner, P.A., a Go-To Thought Leadership Award for Mr. Woessner’s ongoing coverage and analysis of patent disputes, updates to USPTO processes and interviews and profiles of prominent federal agency appointees. He provides NLR's readers with a well-rounded view of issues impacting patent law in the U.S. The cases of Yu v. Apple and CareDx v. Natera are especially notable, detailing the complicated intersections between intellectual property, technology, and health law.
Warren Woessner and his thought leadership on Life Sciences Intellectual Property has been selected for a National Law Review Go-To Thought Leadership Award. Mr. Woessner’s coverage of patent litigation, the Patent Trial and Appeals Board and the Court of Appeals for the Federal Circuit and how those decisions fit into the larger landscape of patent litigation is an invaluable resource for NLR readers. You can subscribe to his Patents 4 Life blog here.